Indigenous Covid-19 vaccine Covaxin has demonstrated interim clinical efficacy of 81 per cent in its phase three trial. The trial involved 25 thousand 800 participants across 21 sites.
The first interim analysis is based on 43 cases of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the Covaxin group resulting in vaccine efficacy of 81 per cent.
The vaccine is developed by Bharat Biotech in partnership with the Indian Council of Medical Research.
Director-General of Indian Council of Medical Research, Dr. Balram Bhargava said that the journey of completely indigenous COVID-19 vaccine in less than eight months’ time showcases the immense strength of Atmanirbhar Bharat. He said, it is also a testament to India’s emergence as a global vaccine superpower.
Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said that Covaxin demonstrated high clinical efficacy against Covid-19 and significant immunogenicity against the rapidly emerging variants.
Support Ethical Journalism. Support The Dispatch
The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism